BioMedWire Stocks

Why Health Insurance Credits Led to the Federal Government Shutdown

Lawmakers in the U.S. Congress hit a stalemate in talks to keep the government open and on Wednesday, a shutdown commenced. At the core of the disagreement between GOP lawmakers and their Democratic Party counterparts are the health care tax credits in the Affordable Care Act due to expire at the end of this year and which the Big Beautiful Bill’s provisions don’t include an extension to these tax credits. 

A lot has been said about the cuts to Medicare and Medicaid under that law, and the refusal to renew those ACA tax credits only piles to the hardship that approximately 22 million Americans will face in getting health cover come next year. 

Democrats in the Senate insist that those credits should be restored as a precondition to approving funding for the government, and the GOP says they are open to discussing that matter, but it shouldn’t be a precondition for keeping government open. Both sides have taken a hardline stance and the government shut down after a spending bill couldn’t get the needed 60 votes to pass in time. 

So, why are those tax credits so important that they have triggered this latest shutdown? The ACA was passed more than a decade back to help individuals who didn’t qualify for Medicaid due to earning above the poverty threshold to access health insurance cover. It also aimed to help those who were unable to get sufficient employer-sponsored health insurance to get the coverage they needed. 

KFF data shows that holders of health coverage obtained through ACA marketplaces nearly doubled after the passing of this Act. This shows how helpful the tax credits are, and continue to be, while they are still in effect. 

Currently, millions of U.S. households are grappling with the high cost of living, and data shows that approximately 4 million individuals could forego getting medical insurance once the tax credits are no longer available. For those who will still wish to retain their coverage, costs are bound to increase substantially, more than doubling in some cases. To put this in context, recent analysis shows that a family that spent $888 in total insurance premiums this year could see their costs hit $1,904 next year. That is a huge increase given the way families are currently struggling to meet their living expenses. 

Already, many people are reporting that the insurance companies from which they obtain coverage have notified them about upcoming increases to their premiums, and other insurers are getting ready to send similar notices. Premium increases so far have hit 50% in some cases. 

Partisan politics aside, this matter is very concerning and all stakeholders need to find a way to lessen the healthcare cost burden on Americans. Logic needs to prevail so that a workable and sustainable solution can be found. Medicare Advantage policy providers like Astiva Health now have an uphill task to continue offering the services they offer to vulnerable groups in these challenging circumstances. 

NOTE TO INVESTORS: The latest news and updates relating to Astiva Health are available in the company’s newsroom at https://ibn.fm/Astiva 

About BioMedWire

BioMedWire (“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire, “Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/Disclaimer

BioMedWire
San Francisco, CA
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is powered by IBN

Chris@BMW

Share
Published by
Chris@BMW

Recent Posts

Rapid Spread of ‘Nightmare Bacteria’ Triggers Alarm

In 2013, former CDC director Tom Frieden observed that there were rising cases of ‘nightmare…

5 days ago

Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment

Sapu Nano received approval from Australia’s Human Research Ethics Committee (“HREC”) to start enrolling patients…

6 days ago

Lantern Pharma Inc.’s (NASDAQ: LTRN) AI-powered PredictBBB.ai Platform Helps Hoth Therapeutics Streamline Candidate Selection in Drug Development

Hoth Therapeutics (NASDAQ: HOTH) is using Lantern Pharma’s (NASDAQ: LTRN) PredictBBB.ai(TM) platform to accelerate development…

6 days ago

FDA Guidance Sets Lantern Pharma Inc. (NASDAQ: LTRN) On a Path Toward Realizing Its Clinical Trial Plans for Rare Pediatric Cancer Therapy

Texas-based clinical-stage biotechnology company Lantern Pharma Inc. is developing a number of clinical trials, using…

7 days ago

Scorpion Venom Shows Promise in Brain Tumor Treatment

The sight of a scorpion moving towards you with its stinger raised can send a…

7 days ago

Soligenix Inc. (NASDAQ: SNGX) Advances Psoriasis Trial with Encouraging Patient Results, Market Potential

Soligenix is positioning itself to expand its presence in dermatology with a novel therapeutic option…

1 week ago